Search Videos and More

Showing 25 - 36 of 575 results

Previous| 1... 2 | 3 | 4 ...48 |Next


Dana-Farber Research News 06.15.2025 News

Dana-Farber Research News 06.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 through May 31.
FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer News

FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test.
Double Negative in Cells Could Undermine PARP Inhibitors News

Double Negative in Cells Could Undermine PARP Inhibitors

There are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors.  
NSCLC Study Presented by Julia Rotow, MD. Video

NSCLC Study Presented by Julia Rotow, MD.

Dr. Julia Rotow presented results from a study using a cell-free DNA (cfDNA)-guided strategy to personalize first-line treatment for advanced non-small cell lung cancer.
Letrozole + Abemaciclib + Metformin Study Presented by Panos Konstantinopoulos, MD, PhD. Video

Letrozole + Abemaciclib + Metformin Study Presented by Panos Konstantinopoulos, MD, PhD.

Dr. Panos Konstantinopoulos presented the first study of a triplet therapy combining letrozole, abemaciclib, and metformin in any cancer type.
PRISM-AC Study Presented by Abby Rosenberg, MD, MS. Video

PRISM-AC Study Presented by Abby Rosenberg, MD, MS.

A new psychosocial intervention is showing promising results for adolescents and young adults (AYA) facing advanced cancer.
Colon Cancer Study Presented by Sara Char, MD. Video

Colon Cancer Study Presented by Sara Char, MD.

A new study shows that consuming an anti-inflammatory diet could extend overall survival after treatment for stage 3 colon cancer.
ARC-20 Study Presented by Toni Choueiri, MD. Video

ARC-20 Study Presented by Toni Choueiri, MD.

Toni Choueiri, MD, of Dana-Farber Cancer Institute presents first results from the ARC-20 trial evaluating casdatifan (HIF-2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell kidney cancer.
Talazoparib + Tazemetostat Presented by Atish Choudhury, MD, PhD. Video

Talazoparib + Tazemetostat Presented by Atish Choudhury, MD, PhD.

Dr. Atish Choudhury presented clinical trial results evaluating the combination of talazoparib and tazemetostat in advanced prostate cancer.
Phase 2 PROSPECT Study Presented by Lakshmi Nayak, MD. Video

Phase 2 PROSPECT Study Presented by Lakshmi Nayak, MD.

Lakshmi Nayak, MD presented results from a phase 2 PROSPECT study focused on tirabrutinib and it's effect on patients with relapsed or refractory primary central nervous system lymphoma.
TRADE Study Presented by Erica Mayer, MD. Video

TRADE Study Presented by Erica Mayer, MD.

Dr. Erica Mayer shares results from the TRADE study showing a successful abemaciclib dose escalation strategy in patients with HR+ breast cancer.
ReACT 1.0 Study Presented by Glenn Hanna, MD. Video

ReACT 1.0 Study Presented by Glenn Hanna, MD.

Dr. Glenn Hanna presented phase 2 data suggesting that circulating HPV DNA could serve as a real-time biomarker to guide treatment intensity in HPV-positive oropharyngeal cancer.

Showing 25 - 36 of 575 results

Previous| 1... 2 | 3 | 4 ...48 |Next